Skip to main content
. 2020 Jun 11;106(7):1867–1875. doi: 10.3324/haematol.2019.239566

Figure 2.

Figure 2.

Post-transplantation minimal residual disease evaluation. At 12 months (M12), 27 of 42 (64%) patients were minimal residual disease negative (MRDneg), 7 of 42 (17%) patients remained MRD positive (MRDpos), 8 of 42 (19%) patients were not evaluable because either prior early toxic death (n=4) and 4 of 42 patients (9.5%) or other reasons including graft rejection (n=2), Eppstein-Barr virus lymproliferation (n=1) and early relapse (n=1).